Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire ...

Treasury Under Secretary for Domestic Finance Jonathan McKernan said he is concerned that the traditional bank funding model ...

United’s Wage Revolution Shapes Midfield RebuildSavings Drive Fuels Long-Term PlanningManchester United’s attempt to reshape ...

Overview: Asian Paints' share price achieved a new 52-week high of Rs. 2,926, on strong buying interest and a demonstrated ...

With stable revenue visibility, strong liquidity, and reliable cash flows, SPC has long been considered one of the more ...

Current change in equity market conditions might revert investors' focus back to Growth-at-a-Reasonable-Price (GARP), one of ...